Showing results (181-190 of 196) with videos related to
Sort By:
Pageof 20
Nature Medicine|November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.Cancer Discovery|March 25, 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging TherapiesEmmet J Jordan, Hyunjae R Kim, Maria E Arcila, et al.JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.Journal of the National Cancer Institute|November 30, 2018
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersJoshua K Sabari, Michael Offin, Dennis Stephens, et al.JCO Precision Oncology|August 22, 2017
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision MakingWassim Abida, Joshua Armenia, Anuradha Gopalan, et al.Nature Medicine|November 15, 2016
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodelingOlga A Guryanova, Kaitlyn Shank, Barbara Spitzer, et al.Blood|September 21, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemiaEric J Duncavage, Adam Bagg, Robert P Hasserjian, et al.Haematologica|March 7, 2024
Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignanciesMelissa Krystel-Whittemore, Kseniya Petrova-Drus, Ryan N Ptashkin, et al.Cancer Discovery|March 28, 2020
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung CancersBob T Li, Flavia Michelini, Sandra Misale, et al.Pageof 20